Answers are grounded in this paper and cite their sources.
The 2020 pipeline has innovations in clinical trials and treatment targets that provide hope for greater success in AD drug development programs. Review of clinical trials over the past 5 years show that there is progressive emphasis on non-amyloid targets, including candidate treatments for inflammation, synapse and neuronal protection, vascular factors, neurogenesis, and epigenetic interventions. There has been a marked growth in repurposed agents in the pipeline.
No takes yet. Share an insight, caveat, or question.
Cummings et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: